Extended dual antithrombotic therapy in patients with chronic coronary syndrome — which agent should be added to aspirin?
According to the 2024ESC Guidelines for the management of chronic coronary syndromes dual antithrombotic treatment comprising aspirin and a second antithrombotic drug for extended long-term prevention should be considered in patients at increased ischemic risk without high bleeding risk. However, no...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Via Medica
2025-06-01
|
| Series: | Cardiology Journal |
| Subjects: | |
| Online Access: | https://journals.viamedica.pl/cardiology_journal/article/view/104821 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849230357270888448 |
|---|---|
| author | Jacek Kubica Piotr Adamski Katarzyna Buszko Piotr Buszman Nader Elmasri Tomasz Fabiszak Jakub Foryś Robert Gajda Mariusz Gąsior Robert Gil Paweł Grzelakowski Tomasz Hajdukiewicz Miłosz Jaguszewski Adam Kern Wacław Kochmann Jacek Konarski Aldona Kubica Tobiasz Kudla Wiktor Kuliczkowski Aleksandra Kusińska-Czyczyło Ewa Laskowska Przemysław Magielski Piotr Michalski Krzysztof Milewski Natalia Mrzywka Piotr Niezgoda Małgorzata Ostrowska Maciej Piasecki Przemysław Podhajski Janusz Prokopczuk Jakub Ratajczak Alicja Rzepka-Cholasińska Grzegorz Skonieczny Giuseppe Specchia Łukasz Szarpak Paweł Szymański Małgorzata Topolska Julia M. Umińska Marcin Ziółkowski Aleksander Żurakowski Eliano Pio Navarese |
| author_facet | Jacek Kubica Piotr Adamski Katarzyna Buszko Piotr Buszman Nader Elmasri Tomasz Fabiszak Jakub Foryś Robert Gajda Mariusz Gąsior Robert Gil Paweł Grzelakowski Tomasz Hajdukiewicz Miłosz Jaguszewski Adam Kern Wacław Kochmann Jacek Konarski Aldona Kubica Tobiasz Kudla Wiktor Kuliczkowski Aleksandra Kusińska-Czyczyło Ewa Laskowska Przemysław Magielski Piotr Michalski Krzysztof Milewski Natalia Mrzywka Piotr Niezgoda Małgorzata Ostrowska Maciej Piasecki Przemysław Podhajski Janusz Prokopczuk Jakub Ratajczak Alicja Rzepka-Cholasińska Grzegorz Skonieczny Giuseppe Specchia Łukasz Szarpak Paweł Szymański Małgorzata Topolska Julia M. Umińska Marcin Ziółkowski Aleksander Żurakowski Eliano Pio Navarese |
| author_sort | Jacek Kubica |
| collection | DOAJ |
| description | According to the 2024ESC Guidelines for the management of chronic coronary syndromes dual antithrombotic treatment comprising aspirin and a second antithrombotic drug for extended long-term prevention should be considered in patients at increased ischemic risk without high bleeding risk. However, no clear indications regarding the choice of a second antithrombotic agent are provided. It was therefore decided to discuss the available evidence regarding this issue. The guidelines provided the number needed to treat (NNT) and the number needed to harm (NNH) for each proposed medication. However, the presented data are misleading and may result in unjustified therapeutic decisions. Due to the great impact of this document on clinical practice all data provided in this document should be carefully verified and commented regarding limitations. |
| format | Article |
| id | doaj-art-8b5008eeca8d4e1a9dd01250069dd484 |
| institution | Kabale University |
| issn | 1897-5593 1898-018X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Via Medica |
| record_format | Article |
| series | Cardiology Journal |
| spelling | doaj-art-8b5008eeca8d4e1a9dd01250069dd4842025-08-21T06:14:13ZengVia MedicaCardiology Journal1897-55931898-018X2025-06-0132310.5603/cj.104821Extended dual antithrombotic therapy in patients with chronic coronary syndrome — which agent should be added to aspirin?Jacek Kubica0Piotr Adamski1Katarzyna Buszko2Piotr Buszman3Nader Elmasri4Tomasz Fabiszak5Jakub Foryś6Robert Gajda7Mariusz Gąsior8Robert Gil9Paweł Grzelakowski10Tomasz Hajdukiewicz11Miłosz Jaguszewski12Adam Kern13Wacław Kochmann14Jacek Konarski15Aldona Kubica16Tobiasz Kudla17Wiktor Kuliczkowski18Aleksandra Kusińska-Czyczyło19Ewa Laskowska20Przemysław Magielski21Piotr Michalski22Krzysztof Milewski23Natalia Mrzywka24Piotr Niezgoda25https://orcid.org/0000-0002-9912-9730Małgorzata Ostrowska26Maciej Piasecki27Przemysław Podhajski28Janusz Prokopczuk29Jakub Ratajczak30Alicja Rzepka-Cholasińska31Grzegorz Skonieczny32Giuseppe Specchia33Łukasz Szarpak34Paweł Szymański35Małgorzata Topolska36Julia M. Umińska37Marcin Ziółkowski38Aleksander Żurakowski39Eliano Pio Navarese40Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandCentre for Cardiovascular Research and Development of American Heart of Poland, Katowice, Gruppo San Donato, Katowice PolandAmerican Heart of Poland, Sztum, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandAmerican Heart of Poland, Zgierz, PolandModern Medical Technologies Center, Torun, Poland3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, PolandDepartment of Cardiology, National Institute of Medicine Ministry of the Internal Affairs and Administration, Warsaw, PolandDepartment of Cardiology and Cardiac Surgery, 10th Military Hospital and Polyclinic, Bydgoszcz, PolandDepartment of Cardiology, Provincial Hospital of Elblag, Poland1st Department of Cardiology, Medical University of Gdansk, Gdansk, PolandDepartment of Cardiology and Internal Medicine, University of Warmia and Mazury in Olsztyn, PolandDepartment of Cardiovascular Disease, Centre of Postgraduate Medical Education, Warsaw, PolandAmerican Heart of Poland, Pila, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandAmerican Heart of Poland, Kedzierzyn-Kozle, PolandClinical Department of Cardiology, Department of Cardiology, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical UniversityAmerican Heart of Poland, Kedzierzyn-Kozle, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandScientia Research Institute, Bydgoszcz, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandAmerican Heart of Poland, Bielsko-Biala, PolandAmerican Heart of Poland, Pila, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandAmerican Heart of Poland, Kedzierzyn-Kozle, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandClinical Department of Cardiology, The Ludwik Rydygier Provincial Polyclinical Hospital, Torun, PolandProfesor emeritus, Department of Cardiology, University of Pavia, ItalyDepartment of Clinical Research and Development, LUXMED Group, Warsaw, PolandRegional Specialistic Hospital, Grudziadz, PolandAmerican Heart of Poland, Katowice, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandAndrzej Frycz Modrzewski Krakow University, PolandClinical Experimental Cardiology, Clinical and Interventional Cardiology, University of Sassari, Sassari, Sardinia Island, ItalyAccording to the 2024ESC Guidelines for the management of chronic coronary syndromes dual antithrombotic treatment comprising aspirin and a second antithrombotic drug for extended long-term prevention should be considered in patients at increased ischemic risk without high bleeding risk. However, no clear indications regarding the choice of a second antithrombotic agent are provided. It was therefore decided to discuss the available evidence regarding this issue. The guidelines provided the number needed to treat (NNT) and the number needed to harm (NNH) for each proposed medication. However, the presented data are misleading and may result in unjustified therapeutic decisions. Due to the great impact of this document on clinical practice all data provided in this document should be carefully verified and commented regarding limitations.https://journals.viamedica.pl/cardiology_journal/article/view/104821extended antithrombotic therapychronic coronary syndromerivaroxabanticagrelorclopidogrelprasugrel |
| spellingShingle | Jacek Kubica Piotr Adamski Katarzyna Buszko Piotr Buszman Nader Elmasri Tomasz Fabiszak Jakub Foryś Robert Gajda Mariusz Gąsior Robert Gil Paweł Grzelakowski Tomasz Hajdukiewicz Miłosz Jaguszewski Adam Kern Wacław Kochmann Jacek Konarski Aldona Kubica Tobiasz Kudla Wiktor Kuliczkowski Aleksandra Kusińska-Czyczyło Ewa Laskowska Przemysław Magielski Piotr Michalski Krzysztof Milewski Natalia Mrzywka Piotr Niezgoda Małgorzata Ostrowska Maciej Piasecki Przemysław Podhajski Janusz Prokopczuk Jakub Ratajczak Alicja Rzepka-Cholasińska Grzegorz Skonieczny Giuseppe Specchia Łukasz Szarpak Paweł Szymański Małgorzata Topolska Julia M. Umińska Marcin Ziółkowski Aleksander Żurakowski Eliano Pio Navarese Extended dual antithrombotic therapy in patients with chronic coronary syndrome — which agent should be added to aspirin? Cardiology Journal extended antithrombotic therapy chronic coronary syndrome rivaroxaban ticagrelor clopidogrel prasugrel |
| title | Extended dual antithrombotic therapy in patients with chronic coronary syndrome — which agent should be added to aspirin? |
| title_full | Extended dual antithrombotic therapy in patients with chronic coronary syndrome — which agent should be added to aspirin? |
| title_fullStr | Extended dual antithrombotic therapy in patients with chronic coronary syndrome — which agent should be added to aspirin? |
| title_full_unstemmed | Extended dual antithrombotic therapy in patients with chronic coronary syndrome — which agent should be added to aspirin? |
| title_short | Extended dual antithrombotic therapy in patients with chronic coronary syndrome — which agent should be added to aspirin? |
| title_sort | extended dual antithrombotic therapy in patients with chronic coronary syndrome which agent should be added to aspirin |
| topic | extended antithrombotic therapy chronic coronary syndrome rivaroxaban ticagrelor clopidogrel prasugrel |
| url | https://journals.viamedica.pl/cardiology_journal/article/view/104821 |
| work_keys_str_mv | AT jacekkubica extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT piotradamski extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT katarzynabuszko extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT piotrbuszman extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT naderelmasri extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT tomaszfabiszak extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT jakubforys extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT robertgajda extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT mariuszgasior extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT robertgil extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT pawełgrzelakowski extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT tomaszhajdukiewicz extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT miłoszjaguszewski extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT adamkern extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT wacławkochmann extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT jacekkonarski extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT aldonakubica extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT tobiaszkudla extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT wiktorkuliczkowski extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT aleksandrakusinskaczyczyło extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT ewalaskowska extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT przemysławmagielski extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT piotrmichalski extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT krzysztofmilewski extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT nataliamrzywka extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT piotrniezgoda extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT małgorzataostrowska extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT maciejpiasecki extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT przemysławpodhajski extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT januszprokopczuk extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT jakubratajczak extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT alicjarzepkacholasinska extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT grzegorzskonieczny extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT giuseppespecchia extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT łukaszszarpak extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT pawełszymanski extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT małgorzatatopolska extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT juliamuminska extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT marcinziołkowski extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT aleksanderzurakowski extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin AT elianopionavarese extendeddualantithrombotictherapyinpatientswithchroniccoronarysyndromewhichagentshouldbeaddedtoaspirin |